TB

Tom Burt

Triton Partners

Greater London, England

Investor
VC

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Biotechnology
Equities
Healthcare
Due Diligence
Valuation
Venture Capital
Private Equity
Investment Banking
Lifesciences
Mergers
Pharmaceutical Industry
Emerging Markets
Investments
Technology Transfer
Financial Modeling
Corporate Development
Corporate Finance
Equity Research
Mergers & Acquisitions
Capital Markets

Education

Investments

Synthace

Series C

Total Funding: $75M

Sphere Fluidics

Series Unknown

Total Funding: $41M

Work Experience

Triton Partners

2023

  • Head of Life Sciences

    2023

Sofinnova Partners

2017 - 2023

  • Partner

    2017 - 2023

    - Investments made into Limflow, MaxCyte, Redx Pharma, Sphere Fluidics & Synthace - Board member: Redx Pharma, SphereFluidics [Interim Chair] & Synthace [Interim Chair]

Peel Hunt

2015 - 2017

  • Senior Research Analyst [Healthcare & Life Sciences]

    2015 - 2017

    Stockbroking and advisory firm serving the UK small & mid-cap market Initiation/ Coverage included: Clinigen, PureTech, Electrical Geo, Abcam, ConvaTec

ARES LIFE SCIENCES LLP

2013 - 2015

  • Investment Director

    2013 - 2015

    Late-venture/growth equity fund investing in EU Healthcare & Life sciences with c.EUR2bn AUM Responsibilities included: - Transaction Management - Investment Oversight/ Portfolio Assistance - Valuation Analysis - Commercial/Technical assessment of new investment opportunities Portfolio: Esaote/ Euromedic/ Santhera/ Stallergenes Examples of Completed Transactions include: Euromedic: concurrent sell-side auction (c. EUR 1bn) and minority s/h acquisition (09/2014). Re-financing (02/2013) and divestment of Czech labs (10/2013) Esaote: minority s/h acquisition (07/2014). Re-financing (07/2015)

Novo A/S

2010 - 2013

  • Associate, Novo Growth Equity

    2010 - 2013

    Late-venture/growth equity division of Novo Holdings investing US$200m p.a in EU/US Healthcare & Life science companies Responsibilities included: - Valuation Analysis - Commercial Assessment - Due Diligence - Investment Oversight/ Portfolio Assistance / Business Development Examples of Completed Transactions include: - Archimedes Pharma Ltd: GBP 65m Series D Investment/ Warburg Pincus stake acquisition - Orexo AB: SEK 150m Secondary purchase/ SEK 111m Convertible loan/ SEK 250m Rights Iss. - Aerocrine AB:SEK 112m Directed Issue/ SEK 112m Convertible loan - Novo A/S DKK 4.1bn Secondary purchase in Chr.Hansen A/S/ US$700m Acquisition of Xellia Pharmaceuticals

Piper Jaffray

2006 - 2010

  • Associate, Healthcare Investment Banking

    2006 - 2010

    European Healthcare/Life Science Investment Banking (M&A/ ECM/ DCM) Examples of Completed Transactions include: - ECM: Santhera CHF 100m IPO / TiGenix €46m IPO / Basilea CHF 324m Follow-on/ NicOx €129m Follow-on/ SkyePharma GBP 21.0m Placing - M&A: Biocompatibles- BrachySciences/ Parexel-ClinPhone/ Protherics-Macromed/ Lonza-Amaxa/ ProStrakan-Cellegy Assets/ BTG-Protherics

GlaxoSmithKline

2001 - 2005

  • Research Engineer

    2001 - 2005

    DNA vaccine production/ scale-up